RxDoctor Payments Data

William Baker

Gynecologic Oncology · Winston Salem, NCNPI 1831331495

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,560 of the $8,906 with a category attached, or 84.9%. Merck accounts for 95.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $8,559 and has fallen 99.4% since, to $49 in 2025.

$8,906in general payments, 2019–2025

Across 27 payments — averaging $329.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$8K
  • AstraZeneca$136
  • Stryker$129
  • Intuitive Surgical$56
  • Tesaro, Inc.$39
  • Johnson & Johnson$28
  • plus $22 from 1 others

What the payments were for

  • Speaking & faculty fees$7,56085%
  • Travel & lodging$4375%
  • Food & beverage$90410%
  • Education$50%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,906 in reported general payments places this provider in the 75th percentile of 52 gynecologic oncology providers in North Carolina.

See all gynecologic oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$86,449
Medicare patients
140
Services billed
665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib17$172,198
XareltoRivaroxaban12$14,335
Estradiol55$2,217
Ondansetron Hcl48$547
Letrozole29$476
Gabapentin33$447
Tamoxifen Citrate11$394
Betamethasone Valerate14$377
Clobetasol Propionate20$357
Lidocaine-PrilocaineLidocaine/Prilocaine26$348
Dexamethasone19$264
Nystatin21$209
Promethazine Hcl30$183
Potassium Chloride27$171
Fluconazole20$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$136$172,19817 claims
Johnson & JohnsonXarelto$28$14,33512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 52 gynecologic oncology providers in North Carolina.

Other gynecologic oncology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →